Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocardial 123I-MIBG Scintigraphy in Aging and Neurodegenerative Disease
NCT05514106Phase 4Enrolling by invitation
- Sponsor
- Mayo Clinic
- Start
- May 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Iobenguane I-123 in Lewy body dementia (LBD), sponsored by Mayo Clinic. Primary endpoint: Correlation of myocardial 123I-MIBG scintigraphy findings with clinical diagnosis at 10 years. Started May 2023; status: enrolling by invitation.
02
Drugs
Iobenguane I-123
03
Conditions
Lewy body dementia (LBD)
Beyond the preview
Go deeper on NCT05514106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514106.